Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
J-TEC Files Mucosal Cell Sheet for Corneal Epithelial Stem Cell Deficiency in Japan
Japan Tissue Engineering (J-TEC) has filed for Japanese regulatory approval of its autologous cultured oral mucosal epithelium COMET01 for the treatment of corneal epithelial stem cell deficiency, the Fujifilm group company said on September 14. COMET01 is a cell sheet…
To read the full story
Related Article
- J-TEC’s Ocural, Cell Sheet for Eye Disease, Launched in Japan
December 13, 2021
- J-TEC’s Oral Mucosal Cell Sheet Ocural Earns NHI Listing
September 16, 2021
- Drug Pricing Rules to Be Applied to Oncolytic Virus Delytact: Chuikyo
June 24, 2021
- Japan Approves J-TEC’s Mucosal Cell Sheet for Corneal Stem Cell Deficiency
June 14, 2021
BUSINESS
- Shionogi/F2G’s Novel Antifungal Makes Mark, New Option in Resistant Cases
June 19, 2026
- Axcelead Joins Lilly’s TuneLab AI Drug Discovery Platform
June 19, 2026
- Create BioVentures Sets Sail as Drug Discovery Bridge Builder
June 19, 2026
- Merck Japan Expands Fertility Benefits, Raises Lifetime Cap to 18 Million Yen
June 19, 2026
- Santen CEO Paid 251 Million Yen in FY2025, COO Joins Disclosure List
June 19, 2026
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…